New Drug Review: Neupro (Rotigotine Transdermal System) for Parkinson's Disease

Neupro is indicated for the treatment of the signs and symtoms of early-stage idiopathic Parkinson's disease. Key points about Neupro:
1. Offers simple, once-daily dosing
2. Available patch: 2mg/24 hr, 4mg/24hr, 6mg/24hr
3. Most commonly reported side effects: nausea, application site reactions, somnolence, dizziness, headache, vomiting, and insomnia
4. Neupro should be used with caution in patients, especially those at risk for cardiovascular disease, because of the potential for symptomatic hypotension, syncope, elevated heart rate, elevated blood pressure, fluid retension, and/or weight gain
Neupro is manufactured by Schwarz Pharma. For more information please go to: http://www.neupro.com/